Comments Open on End of NIH Review for Gene Therapy Studies
NIH oversight panel no longer plans to review all applications for gene therapy experiments
FDA Permits Marketing of Brain Stimulation Device for OCD
FDA previously approved transcranial magnetic stimulation for major depression, certain migraines
Steps Provided for Discharging Patient From Practice
Letter should be sent informing patient of their discharge, providing at least 30 days' notice
Patient Portals Don’t Appear to Have Much Traction
Patients not accessing them, physicians not using full range of features
Opioid Dependence More Common Before Spine Surgery
Findings based on large study of patients having surgery for degenerative spondylolisthesis
ACA Coverage Gains Include Workers Without Insurance
Reduction in uninsurance rate among this group larger than that of not-employed adults
Practice Names, Logos Should Be Carefully Designed
The logo should be simple and easy to identify, should send a message about the medical practice
Methylphenidate Good First-Choice Pediatric ADHD Drug
For adults, amphetamines are reasonable first choice to treat attention-deficit hyperactivity disorder
NIH Panel Will No Longer Review Gene Therapy Experiments
FDA will now assess gene therapy experiments and products as it does with other treatments, drugs
Rate of Pediatric Emergencies in Ambulatory Practices Identified
Most due to respiratory distress, psychiatric/behavioral emergencies, or seizures
